NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Thermo Fisher Scientific' stock, noting the firm's increased scale as a result of its purchase of Life Technologies, as well as improving end markets.

The investment bank lifted Thermo Fisher's shares to a Buy rating from a previous Neutral rating and increased the 12-month price target on its stock to $153 from $114.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.